Moreover, there is an increased frequency of SMAD4 alterations in ovarian metastases from CRC, suggesting that the oncogenic properties conferred by aberrant TGF-β signaling may contribute to CRC metastasis to the ovaries [58]. This evidence concerns the gene TGFB1 and colorectal carcinoma.